{"transactions":[{"id":3507525,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":2,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":3,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B1 Preferred Shares","published_at":"2019-05-30T21:26:55.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":13169,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners. L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein"}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":13169},"source":{"system":"sec-edgar","filing":"0001104659-19-032917","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1482194/000110465919032917/a4.xml","form_type":"4"}},{"id":3507524,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":2,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":3,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Shares","published_at":"2019-05-30T21:26:55.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":18485,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners. L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein"}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":18485},"source":{"system":"sec-edgar","filing":"0001104659-19-032917","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1482194/000110465919032917/a4.xml","form_type":"4"}},{"id":3507523,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":2,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":3,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B1 Preferred Shares","published_at":"2019-05-30T21:26:55.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":623196,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":623196},"source":{"system":"sec-edgar","filing":"0001104659-19-032917","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1482194/000110465919032917/a4.xml","form_type":"4"}},{"id":3507522,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":2,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":3,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Shares","published_at":"2019-05-30T21:26:55.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":874709,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":874709},"source":{"system":"sec-edgar","filing":"0001104659-19-032917","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1482194/000110465919032917/a4.xml","form_type":"4"}},{"id":3507521,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":2,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":3,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-30T21:26:55.000Z","date":"2019-05-28","kind":"purchase","acquired":true,"shares":7983,"price":14,"value":111762.0,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners. L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein"}],"balance_after":39637,"source":{"system":"sec-edgar","filing":"0001104659-19-032917","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1482194/000110465919032917/a4.xml","form_type":"4"}},{"id":3507520,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":2,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":3,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-30T21:26:55.000Z","date":"2019-05-28","kind":"purchase","acquired":true,"shares":377732,"price":14,"value":5288248.0,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":1875637,"source":{"system":"sec-edgar","filing":"0001104659-19-032917","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1482194/000110465919032917/a4.xml","form_type":"4"}},{"id":3507519,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":2,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":3,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-30T21:26:55.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":13169,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners. L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein"}],"balance_after":31654,"source":{"system":"sec-edgar","filing":"0001104659-19-032917","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1482194/000110465919032917/a4.xml","form_type":"4"}},{"id":3507518,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":2,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":3,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-30T21:26:55.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":18485,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners. L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein"}],"balance_after":18485,"source":{"system":"sec-edgar","filing":"0001104659-19-032917","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1482194/000110465919032917/a4.xml","form_type":"4"}},{"id":3507517,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":2,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":3,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-30T21:26:55.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":623196,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":1497905,"source":{"system":"sec-edgar","filing":"0001104659-19-032917","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1482194/000110465919032917/a4.xml","form_type":"4"}},{"id":3507516,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":2,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":3,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-30T21:26:55.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":874709,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":874709,"source":{"system":"sec-edgar","filing":"0001104659-19-032917","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1482194/000110465919032917/a4.xml","form_type":"4"}},{"id":3804484,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":193492,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5320},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":36,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804483,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":141249,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5721},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":35,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804482,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":194786,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7207},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":34,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804481,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":9155794,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":251783},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":33,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804480,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":6683697,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":270690},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804479,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":9217015,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":341030},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804478,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":52183,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Strategic Partners, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1931},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804477,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":106019,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Strategic Partners, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6128},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804476,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":17533,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Strategic Partners, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":758},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804475,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":5462550,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III (LP1), L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":202115},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804474,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":11097596,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III (LP1), L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":641440},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804473,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":1835270,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III (LP1), L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":79467},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804472,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":64815,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Co-Investment, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2399},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804471,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":131683,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Co-Investment, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7610},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804470,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":21776,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Co-Investment, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":943},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804469,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-09-27","kind":"exercise","acquired":true,"shares":4978,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Strategic Partners L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":52183,"derivative":{"underlying":"Common Stock","underlying_shares":184},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804468,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock Warrant (right to buy)","published_at":"2018-10-01T17:28:38.000Z","date":"2018-09-27","kind":"exercise","acquired":false,"shares":4978,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Strategic Partners L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":4315,"derivative":{"exercise_price":0.4797,"underlying":"Series C Preferred Stock","underlying_shares":4978},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804467,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-09-27","kind":"exercise","acquired":true,"shares":521159,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III (LPI) L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":5462550,"derivative":{"underlying":"Common Stock","underlying_shares":19282},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804466,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock Warrant (right to buy)","published_at":"2018-10-01T17:28:38.000Z","date":"2018-09-27","kind":"exercise","acquired":false,"shares":521159,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III (LPI) L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":451869,"derivative":{"exercise_price":0.4797,"underlying":"Series C Preferred Stock","underlying_shares":521159},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804465,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-09-27","kind":"exercise","acquired":true,"shares":6183,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Co-Investment, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":64815,"derivative":{"underlying":"Common Stock","underlying_shares":228},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804464,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock Warrant (right to buy)","published_at":"2018-10-01T17:28:38.000Z","date":"2018-09-27","kind":"exercise","acquired":false,"shares":6183,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Co-Investment, L.P."},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":5361,"derivative":{"exercise_price":0.4797,"underlying":"Series C Preferred Stock","underlying_shares":6183},"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804463,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":5320,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":18248,"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804462,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":5721,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":12928,"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804461,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":7207,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V Strategic Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":7207,"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804460,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":251783,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of the issuer's Series E Preferred Stock automatically converted into 0.0275 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":863503,"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804459,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":270690,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of the issuer's Series D Preferred Stock automatically converted into 0.0405 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":611720,"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804458,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":341030,"ownership":{"direct":false,"nature":"By SV Life Sciences Fund V, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":341030,"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804457,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":1931,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Strategic Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":8817,"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804456,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":6128,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Strategic Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":6886,"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804455,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":758,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Strategic Partners, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":758,"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804454,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":202115,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III (LP1), L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":923022,"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804453,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":641440,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III (LP1), L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":720907,"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804452,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":79467,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III (LP1), L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":79467,"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804451,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":2399,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Co-Investment, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of the issuer's Series C Preferred Stock automatically converted into 0.0370 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":10952,"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804450,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":7610,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Co-Investment, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the issuer's Series B Preferred Stock automatically converted into 0.0578 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":8553,"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":3804449,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163332,"kind":"organization","name":"ILSF III, LLC","position":2,"cik":"0001630791","reported_name":"ILSF III, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163333,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","position":3,"cik":"0001630790","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163334,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","position":4,"cik":"0001233226","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163335,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","position":5,"cik":"0001233315","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":163336,"kind":"organization","name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","position":6,"cik":"0001172861","reported_name":"INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157096,"kind":"organization","name":"SV Life Sciences Fund V (GP), LP","position":7,"cik":"0001644146","reported_name":"SV Life Sciences Fund V (GP), LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":8,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":9,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-10-01T17:28:38.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":943,"ownership":{"direct":false,"nature":"By International Life Sciences Fund III Co-Investment, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock automatically converted into 0.0433 share of the issuer's Common Stock on October 1, 2018 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the \"IPO\") pursuant to a registration statement on Form S-1 (File No. 333-227103) under the Securities Act of 1933, as amended (the \"Registration Statement\"), and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"International Life Sciences Fund III (GP), LP. (\"Fund III GP\") is the general partner of each of: (i) International Life Sciences Fund III (LP1), L.P. (\"ILSF LP1\"), (ii) International Life Sciences Fund III Co-Investment, L.P. (\"ILSF Co-Invest\") and (iii) International Life Sciences Fund III Strategic Partners, L.P. (\"ILSF Strategic\" and collectively, the \"Fund III Entities\"). ILSF III, LLC (the \"ILSF General Partner\") is the general partner of Fund III GP and, through an investment committee comprised of James Garvey, Kate Bingham, Eugene D. Hill, III and Michael J. Ross controls voting and investment decisions over the Issuer's shares held by the Fund III Entities by majority vote. Each of Fund III GP, ILSF General Partner, and each member of the investment committee of ILSF General Partner disclaims beneficial ownership over the Shares held by the Fund III Entities except to the extent of any pecuniary interest therein."}],"balance_after":943,"source":{"system":"sec-edgar","filing":"0001209191-18-052851","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172861/000120919118052851/doc4.xml","form_type":"4"}},{"id":4156464,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":50477,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F9","text":"These shares are owned directly by SV Life Sciences Fund VI Strategic Partners, L.P. (\"SVLS VI SPP\"). SVLS VI GP is the general partner of SVLS VI SPP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn, and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI SPP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":14789},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156463,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":1474348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"These shares are owned directly by SV Life Sciences Fund VI, L.P. (\"SVLS VI LP\"). SV Life Sciences Fund VI (GP), LP (\"SVLS VI GP\") is the general partner of SVLS VI LP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI LP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":431980},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156462,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":14635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4288},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156461,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":692552,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":202915},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156460,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":4747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2365},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156459,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":224665,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":111955},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156458,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":15246,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6806},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156457,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":721402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":322102},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156456,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":14587,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5219},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156455,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":690259,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":247010},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156454,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":1380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":404},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156453,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":false,"shares":65287,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19128},"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156452,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"purchase","acquired":true,"shares":16552,"price":10,"value":165520.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F9","text":"These shares are owned directly by SV Life Sciences Fund VI Strategic Partners, L.P. (\"SVLS VI SPP\"). SVLS VI GP is the general partner of SVLS VI SPP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn, and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI SPP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":1868961,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156451,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"purchase","acquired":true,"shares":483448,"price":10,"value":4834480.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"These shares are owned directly by SV Life Sciences Fund VI, L.P. (\"SVLS VI LP\"). SV Life Sciences Fund VI (GP), LP (\"SVLS VI GP\") is the general partner of SVLS VI LP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI LP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":1852409,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156450,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":14789,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F9","text":"These shares are owned directly by SV Life Sciences Fund VI Strategic Partners, L.P. (\"SVLS VI SPP\"). SVLS VI GP is the general partner of SVLS VI SPP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn, and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI SPP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":1368961,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156449,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":431980,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F8","text":"These shares are owned directly by SV Life Sciences Fund VI, L.P. (\"SVLS VI LP\"). SV Life Sciences Fund VI (GP), LP (\"SVLS VI GP\") is the general partner of SVLS VI LP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI LP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":1354172,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156448,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":4288,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":922192,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156447,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":202915,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":917904,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156446,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":2365,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":714989,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156445,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":111955,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":712624,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156444,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":6806,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":600669,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156443,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":322102,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":593863,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156442,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":5219,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":271761,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156441,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":247010,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":266542,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156440,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":404,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. (\"SVLS V SPP\"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":19532,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}},{"id":4156439,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":157094,"kind":"organization","name":"SVLSF V, LLC","position":1,"cik":"0001644160","reported_name":"SVLSF V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154548,"kind":"organization","name":"SV Life Sciences Fund VI Strategic Partners, L.P.","position":2,"cik":"0001667605","reported_name":"SV Life Sciences Fund VI Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":154547,"kind":"organization","name":"SV Life Sciences Fund VI, L.P.","position":3,"cik":"0001642251","reported_name":"SV Life Sciences Fund VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157097,"kind":"organization","name":"SV Life Sciences Fund V Strategic Partners, L.P.","position":4,"cik":"0001482194","reported_name":"SV Life Sciences Fund V Strategic Partners, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":157095,"kind":"organization","name":"SV LIFE SCIENCES FUND V LP","position":5,"cik":"0001460732","reported_name":"SV LIFE SCIENCES FUND V LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-11-20T17:37:04.000Z","date":"2017-11-20","kind":"exercise","acquired":true,"shares":19128,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"These shares are owned directly by SV Life Sciences Fund V, L.P. (\"SVLS V LP\"). SV Life Sciences Fund V (GP), LP (\"SVLS V GP\") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein."}],"balance_after":19128,"source":{"system":"sec-edgar","filing":"0000899243-17-027009","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1667605/000089924317027009/doc4.xml","form_type":"4"}}]}